STE · 10-Q · 2026Q3 · Full report

Products and Technology

STERIS plc · 2026-11-05 · Importance 23 · Surprise 24

STERIS’s fiscal 2027 R&D initiatives emphasize sterile processing technologies, procedural products and accessories, and devices and support accessories used in gastrointestinal endoscopy procedures. The company says it is improving innovation governance and leveraging technology to accelerate development of critical capital and consumable products. Its offerings include infection-prevention consumables, endoscopy accessories, procedural instruments, sterilizers, automated endoscope reprocessors, and operating-room infrastructure.

Key facts

• STERIS states that compliance requirements or pending or threatened litigation could delay, limit, or prevent product or service introductions, affect production, supply, or marketing, or result in uncovered costs. source
• During fiscal 2027, STERIS R&D investments focused on sterile processing technologies, procedural products and accessories, and devices and support accessories used in gastrointestinal endoscopy procedures. source